Karolinska Institutet operates a unique marketing solution for academic research
Karolinska Institutets solution for the financing of early discoveries will be presented at the biotech fair in Philadelphia on 21 June.
A portfolio of start-ups is created and an investment base is sought for the entire package. The system used at Karolinska Institutet is unique in the world, and creates better chances of success as well as healthy earnings for the investors.
The university is forever generating new science of considerable market potential. However, the lack of venture capital to cover the cost of early product development is just one of the problems hampering the commercialisation of scientific discoveries.
Karolinska Institutet has solved this problem in a unique way by forming portfolio companies. To date two such companies have been set up, named Karolinska Development I and II. Karolinska Development I comprises 16 start-ups and Karolinska Development II 18. Investors support the entire portfolio, and since their capital is invested in several different companies, their risks decrease in inverse proportion to their chances of success. The portfolio companies are supported by Karolinska Development until they are ready to launch their applications onto the market.
“Pretty much all universities help their research teams to market their discoveries,” says Ola Flink, investment manager at Karolinska Development. “Weve solved the main problem of getting financing for such early discoveries in a hugely successful way. Our solution gives investors a greater chance of generating healthy returns as they invest their money in several different companies.”
All latest news from the category: Business and Finance
This area provides up-to-date and interesting developments from the world of business, economics and finance.
A wealth of information is available on topics ranging from stock markets, consumer climate, labor market policies, bond markets, foreign trade and interest rate trends to stock exchange news and economic forecasts.
Prostate cancer organoids open path to precision oncology
A multi-institutional team of investigators led by bioengineer Ankur Singh has developed research tools that shed new light on a virtually untreatable form of prostate cancer, opening a pathway that may lead…
Experimental compound counters diabetic complications
An experimental compound reduced complications of type 1 and type 2 diabetes in mice – not by lowering blood sugar – but by countering its consequences: cell death, inflammation, and…